Monoclonal Antibody Therapy in Treating Patients With Metastatic Renal Cell Cancer

Part of paid clinical trials in Bethesda, Maryland.

Sponsor
National Institutes of Health Clinical Center (CC)
Study ID
NCT00057889
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
16 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. PURPOSE: Phase II trial to study the effectiveness of monoclonal antibody therapy in treating patients who have metastatic renal cell cancer (kidney cancer) that is refractory to treatment with interleukin-2 or unable to be treated with interleukin-2.

Key Dates

Start date
Feb 28, 2003
Status verified
Mar 2012
Primary completion
Oct 31, 2007
Completion
Feb 29, 2008

Study Design

Primary purpose
TREATMENT

Locations (1)

FacilityCityStateZIPSite coordinators
Warren Grant Magnuson Clinical Center - NCI Clinical Studies SupportBethesdaMaryland20892-1182-

Find similar trials in Bethesda, MD

By condition
Kidney cancer
By specialty
OncologyUrology
By research site
Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support· Bethesda, MD

Related Studies